Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms CheckMate 744
- Sponsors Bristol-Myers Squibb
- 11 Jul 2024 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 05 Jul 2024 Status changed from active, no longer recruiting to completed.
- 21 Jun 2024 This trial has been completed in Germany (Global end date: 28 May 2024).